Nature Reviews Urology最新文献

英文中文

Author Correction: Advances in sliding clip renorrhaphy for partial nephrectomy. 作者更正：用于肾部分切除术的滑动夹肾切除术的进展。

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-07-05 DOI: 10.1038/s41585-024-00915-6

David Homewood, Tayla Fay, Nicholas Tan, Andrew Silagy, Niall M Corcoran, Nathan Lawrentschuk, Dinesh Agarwal

引用次数: 0

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. CRISPR-Cas9 在确定肌肉浸润性膀胱癌新治疗靶点方面的潜力。

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-07-01 DOI: 10.1038/s41585-024-00901-y

Danielle J Smith, Sapna Lunj, Antony D Adamson, Sankari Nagarajan, Tim A D Smith, Kimberley J Reeves, Peter J Hoskin, Ananya Choudhury

Gene editing technologies help identify the genetic perturbations driving tumour initiation, growth, metastasis and resistance to therapeutics. This wealth of information highlights tumour complexity and is driving cancer research towards precision medicine approaches based on an individual's tumour genetics. Bladder cancer is the 11th most common cancer in the UK, with high rates of relapse and low survival rates in patients with muscle-invasive bladder cancer (MIBC). MIBC is highly heterogeneous and encompasses multiple molecular subtypes, each with different responses to therapeutics. This evidence highlights the need to identify innovative therapeutic targets to address the challenges posed by this heterogeneity. CRISPR-Cas9 technologies have been used to advance our understanding of MIBC and determine novel drug targets through the identification of drug resistance mechanisms, targetable cell-cycle regulators, and novel tumour suppressor and oncogenes. However, the use of these technologies in the clinic remains a substantial challenge and will require careful consideration of dosage, safety and ethics. CRISPR-Cas9 offers considerable potential for revolutionizing bladder cancer therapies, but substantial research is required for validation before these technologies can be used in the clinical setting.

基因编辑技术有助于确定驱动肿瘤发生、生长、转移和抗药性的基因扰动。这些丰富的信息凸显了肿瘤的复杂性，并推动着癌症研究向基于个体肿瘤遗传学的精准医疗方法发展。膀胱癌是英国第 11 位最常见的癌症，肌层浸润性膀胱癌（MIBC）患者复发率高、存活率低。肌层浸润性膀胱癌具有高度异质性，包括多种分子亚型，每种亚型对疗法的反应各不相同。这些证据凸显了确定创新治疗靶点的必要性，以应对这种异质性带来的挑战。CRISPR-Cas9技术已被用于推进我们对MIBC的了解，并通过鉴定耐药机制、可靶向的细胞周期调节因子以及新型抑癌基因和致癌基因来确定新型药物靶点。然而，在临床中使用这些技术仍是一项巨大的挑战，需要仔细考虑用量、安全性和伦理问题。CRISPR-Cas9为膀胱癌疗法的变革提供了巨大的潜力，但在这些技术应用于临床之前，还需要大量的研究来验证。

{"title":"CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer.","authors":"Danielle J Smith, Sapna Lunj, Antony D Adamson, Sankari Nagarajan, Tim A D Smith, Kimberley J Reeves, Peter J Hoskin, Ananya Choudhury","doi":"10.1038/s41585-024-00901-y","DOIUrl":"https://doi.org/10.1038/s41585-024-00901-y","url":null,"abstract":"Gene editing technologies help identify the genetic perturbations driving tumour initiation, growth, metastasis and resistance to therapeutics. This wealth of information highlights tumour complexity and is driving cancer research towards precision medicine approaches based on an individual's tumour genetics. Bladder cancer is the 11th most common cancer in the UK, with high rates of relapse and low survival rates in patients with muscle-invasive bladder cancer (MIBC). MIBC is highly heterogeneous and encompasses multiple molecular subtypes, each with different responses to therapeutics. This evidence highlights the need to identify innovative therapeutic targets to address the challenges posed by this heterogeneity. CRISPR-Cas9 technologies have been used to advance our understanding of MIBC and determine novel drug targets through the identification of drug resistance mechanisms, targetable cell-cycle regulators, and novel tumour suppressor and oncogenes. However, the use of these technologies in the clinic remains a substantial challenge and will require careful consideration of dosage, safety and ethics. CRISPR-Cas9 offers considerable potential for revolutionizing bladder cancer therapies, but substantial research is required for validation before these technologies can be used in the clinical setting.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-clear cell differentiated renal cell carcinoma — a new therapeutic target 去透明细胞分化型肾细胞癌--新的治疗目标

IF 15.3 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-27 DOI: 10.1038/s41585-024-00911-w

Keith A. Lawson, W. Marston Linehan

Reprogrammed metabolism has been long recognized as a driver of kidney cancer progression, prompting efforts to develop metabolic targeted therapies against this disease. Evidence offers further clarity on the metabolic phenotypes associated with aggressive disease, expanding the potential target space for attacking these tumours at their metabolic roots.

重新编程的新陈代谢长期以来一直被认为是肾癌进展的驱动因素，这促使人们努力开发针对这种疾病的新陈代谢靶向疗法。有证据进一步阐明了与侵袭性疾病相关的代谢表型，从而扩大了从代谢根源攻击这些肿瘤的潜在靶点空间。

引用次数: 0

Advances in sliding clip renorrhaphy for partial nephrectomy. 用于肾部分切除术的滑动夹式肾切除术的进展。

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-25 DOI: 10.1038/s41585-024-00906-7

David Homewood, Tayla Fay, Nicholas Tan, Andrew Silagy, Niall M Corcoran, Nathan Lawrentschuk, Dinesh Agarwal

引用次数: 0

Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis. 肾肿块活检--一种实用且与临床病理相关的诊断方法。

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-21 DOI: 10.1038/s41585-024-00897-5

Hussein Mansour, My-Anh Tran-Dang, Miles Walkden, Ekaterini Boleti, Ravi Barod, Prasad Patki, Faiz Mumtaz, Maxine G B Tran, Axel Bex, Soha El Sheikh

Advancements in imaging modalities have increased the frequency of renal mass discovery. Imaging has typically been considered sufficient to guide management for a large proportion of these tumours, but renal mass biopsies (RMBs) have an increasing role in determining malignancy and can be a valuable tool for preventing unnecessary surgery in patients with benign tumours. A structured approach should be used to help to navigate the expanding repertoire of renal tumours, many of which are molecularly defined. In terms of tumour subtyping, the pathologist's strategy should focus on stratifying patients into clinically different prognostic groups according to our current knowledge of tumour behaviour, including benign, low-grade or indolent, intermediate malignant or highly aggressive. Crucial pathological features and morphological mimicry of tumours can alter the tumour's prognostic group. Thus, pathologists and urologists can use RMB to select patients with tumours at a reduced risk of progression, which can be safely managed with active surveillance within a tailored imaging schedule, versus tumours for which ablation or surgical intervention is indicated. RMB is also crucial in the oncological setting to distinguish between different high-grade tumours and guide tailored management strategies.

成像模式的进步增加了肾肿块的发现频率。影像学通常被认为足以指导大部分此类肿瘤的治疗，但肾肿块活检（RMBs）在确定恶性程度方面发挥着越来越重要的作用，是避免良性肿瘤患者接受不必要手术的重要工具。应采用一种结构化的方法来帮助了解不断扩大的肾肿瘤种类，其中许多肿瘤都有分子定义。就肿瘤亚型而言，病理学家的策略应侧重于根据我们目前对肿瘤行为的了解，将患者分为临床上不同的预后组别，包括良性、低度或轻度、中度恶性或高度侵袭性。肿瘤的关键病理特征和形态学模拟可改变肿瘤的预后分组。因此，病理学家和泌尿科医生可以利用红外线成像技术来选择肿瘤进展风险较低的患者，这些患者可以通过量身定制的成像计划进行积极的监测，从而安全地控制肿瘤的进展。在肿瘤学领域，红外线成像对于区分不同的高级别肿瘤和指导量身定制的管理策略也至关重要。

{"title":"Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.","authors":"Hussein Mansour, My-Anh Tran-Dang, Miles Walkden, Ekaterini Boleti, Ravi Barod, Prasad Patki, Faiz Mumtaz, Maxine G B Tran, Axel Bex, Soha El Sheikh","doi":"10.1038/s41585-024-00897-5","DOIUrl":"https://doi.org/10.1038/s41585-024-00897-5","url":null,"abstract":"Advancements in imaging modalities have increased the frequency of renal mass discovery. Imaging has typically been considered sufficient to guide management for a large proportion of these tumours, but renal mass biopsies (RMBs) have an increasing role in determining malignancy and can be a valuable tool for preventing unnecessary surgery in patients with benign tumours. A structured approach should be used to help to navigate the expanding repertoire of renal tumours, many of which are molecularly defined. In terms of tumour subtyping, the pathologist's strategy should focus on stratifying patients into clinically different prognostic groups according to our current knowledge of tumour behaviour, including benign, low-grade or indolent, intermediate malignant or highly aggressive. Crucial pathological features and morphological mimicry of tumours can alter the tumour's prognostic group. Thus, pathologists and urologists can use RMB to select patients with tumours at a reduced risk of progression, which can be safely managed with active surveillance within a tailored imaging schedule, versus tumours for which ablation or surgical intervention is indicated. RMB is also crucial in the oncological setting to distinguish between different high-grade tumours and guide tailored management strategies.","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":" ","pages":""},"PeriodicalIF":12.1,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The bladder tumour microbiome and BCG response 膀胱肿瘤微生物群与卡介苗反应

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-18 DOI: 10.1038/s41585-024-00910-x

Louise Lloyd

引用次数: 0

Progression-free survival end points in prostate cancer: are we truly making progress 前列腺癌无进展生存期终点：我们是否真正取得了进展

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-17 DOI: 10.1038/s41585-024-00902-x

Ravi A. Madan, Edwin M. Posadas, Richard J. Lee

Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.

最近，一些前列腺癌治疗策略仅凭无进展生存期获监管部门批准，这是前列腺癌治疗发展过程中的一个相对变化。在此之前，总生存期是获得批准的必要条件。这种方法是否有必要或对患者是否有益仍不清楚。

引用次数: 0

Single-cell penile cancer atlas to identify disease drivers 单细胞阴茎癌图谱确定疾病驱动因素

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-14 DOI: 10.1038/s41585-024-00909-4

Maria Chiara Masone

引用次数: 0

Promising efficacy of UTI vaccines as an alternative to antibiotics 尿毒症疫苗替代抗生素的疗效令人期待

IF 15.3 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-14 DOI: 10.1038/s41585-024-00905-8

Quentin Mak, Julian Greig, Prokar Dasgupta, Sachin Malde, Nicholas Raison

Antibiotics are the mainstay prophylaxis and treatment for recurrent urinary tract infections (UTIs). However, antibiotic resistance is rising globally, leading to infections that are harder to treat. In view of this resistance, alternative, non-antibiotic treatments for recurrent UTIs are now being developed; among them, UTI vaccines have shown promising results.

抗生素是预防和治疗复发性尿路感染（UTI）的主要药物。然而，抗生素耐药性在全球范围内不断上升，导致感染更加难以治疗。鉴于这种抗药性，目前正在开发治疗复发性尿路感染的非抗生素替代疗法；其中，尿路感染疫苗已显示出良好的效果。

引用次数: 0

A new signalling-based system for germ cell reprogramming 基于信号的生殖细胞重编程新系统

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology

Pub Date : 2024-06-13 DOI: 10.1038/s41585-024-00907-6

Maria Chiara Masone

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Nature Reviews Urology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀